Locations:
SearchAdvertisement
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Dispelling myths and sharing practical experiences
Distinct molecular features found in five subtypes of disease
Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Advertisement
Advertisement